Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute

July 18, 2022 updated by: Mahmoud Ahmed Agamy, Assiut University

Frequency of SARS COV-2 Infection Among Malignant Patients at South Egypt Cancer Institute

Assessment the frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute

Study Overview

Status

Not yet recruiting

Conditions

COVID-19

Intervention / Treatment

Other: disease

Detailed Description

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age Cancer is one of the most common examples of immunocompromised states

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: mahmoud ahmed agamy, post graduate
Phone Number: 01017989744
Email: mahmoudahmedatm@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients at south Egypt cancer institute

Description

Inclusion Criteria:

Malignant patients.
PCR positive for covid-19

Exclusion Criteria:

PCR negative for covid-19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
calculate the frequency of SARS-CoV-2 infection among patients with malignant data collection during the study period Time Frame: 1 year	To calculate the rate of SARS-CoV-2 infection among patients with malignant data collection within covid-19 pandemic either retrospective or prospective. Data will include : patient demography such as Age,sex,smoking status,cancer type cancer treatment (patient on chemotherapy or radiotherapy if available), symptoms, signs and laboratory parameters of COVID -19. outcome including hospitalization or ICU admission and mortality rate will be recorded	1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 1, 2022

Primary Completion (Anticipated)

July 1, 2023

Study Completion (Anticipated)

August 1, 2023

Study Registration Dates

First Submitted

July 13, 2022

First Submitted That Met QC Criteria

July 18, 2022

First Posted (Actual)

July 20, 2022

Study Record Updates

Last Update Posted (Actual)